Search results

Order by: most recent most popular relevance

Jurisdiction

Work area

Firm name

Date from

Date to

Results: 1-10 of 1,513

PTAB Denies Another IPR Petition Relating to Adalimumab

Rothwell, Figg, Ernst & Manbeck, PC
USA
June 14 2018

The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of AbbVie’s patent, U.S

Novartis and Amgen Announce FDA Approval of Aimovig

Rothwell, Figg, Ernst & Manbeck, PC
USA
May 23 2018

Last week, Novartis and Amgen announced the FDA approved Aimovig (erenumab) for the preventive treatment of migraine in adults. The FDA granted

CRISPR dust-up; compulsory licensing in China; Novartis CEO wants US reform, and more April's Life Sciences IP Round-up

IAM
USA, China, Global, India
May 7 2018

In this month’s round-up of life sciences-related patent news, we report on the year’s first pharma mega-merger, the latest developments in a

CJEU: concerted practice designed to reduce off-label use of a medicinal product to increase use of another

Accura Advokatpartnerselskab
Denmark, European Union
April 26 2018

In a recent judgment from January 2018 the Court of Justice of the European Union (CJEU) confirmed that concerted provision of misleading information

Side CAR-Ts

Bristows LLP
United Kingdom, European Union
April 7 2018

Big pharma's interest in chimeric antigen receptor (CAR)-T therapies is clear: companies such as Novartis and Pfizer have been making large

Win or Go Home? Standing to Appeal PTAB Decisions Upholding Patentability to the Federal Circuit Before Submitting a Biosimilar Marketing Application

Patterson Belknap Webb & Tyler LLP
USA
April 6 2018

Biosimilar developers have been aggressive in filing petitions for inter partes reviews (IPRs) of biologics patents before the Patent Trial and Appeal

Additional Discovery of Clinical Trial Data in Inter Partes Review

Baker & Hostetler LLP
USA
March 30 2018

In Apotex, Inc. et al. v. Novartis AG (IPR 2017-00854, paper 47 dated Feb. 5, 2018), petitioner Apotex sought, and was granted, discovery of a Phase

Additional Discovery of Clinical Trial Data in Inter Partes Review

Baker & Hostetler LLP
USA
March 30 2018

In Apotex, Inc. et al. v. Novartis AG (IPR 2017-00854, paper 47 dated Feb. 5, 2018), petitioner Apotex sought, and was granted, discovery of a Phase

Marijuana Series: "Big Pharma's" Entry Into the Cannabis Market

Porzio Bromberg & Newman PC
Canada
March 20 2018

Tilray is a federally licensed producer of medical cannabis products in Canada. On March 19, Tilray made big news in Canada, and around the world

Supreme Court overrules both lower tribunals to recognise inventiveness

Kim & Chang
South Korea
March 19 2018

The Supreme Court recently issued decisions recognising the inventiveness of two Novartis patents for a compound and a transdermal composition. The

Current Search

Refine

Content type

Tags

Jurisdiction

Work area

Firm name

Author

Territory

Search results

Results: 1-10 of 1,513

PTAB Denies Another IPR Petition Relating to Adalimumab

Novartis and Amgen Announce FDA Approval of Aimovig

CRISPR dust-up; compulsory licensing in China; Novartis CEO wants US reform, and more April's Life Sciences IP Round-up

CJEU: concerted practice designed to reduce off-label use of a medicinal product to increase use of another

Side CAR-Ts

Win or Go Home? Standing to Appeal PTAB Decisions Upholding Patentability to the Federal Circuit Before Submitting a Biosimilar Marketing Application

Additional Discovery of Clinical Trial Data in Inter Partes Review

Additional Discovery of Clinical Trial Data in Inter Partes Review

Marijuana Series: "Big Pharma's" Entry Into the Cannabis Market

Supreme Court overrules both lower tribunals to recognise inventiveness